Darlifarnib

Overview

Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti- VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment.

Application

Products | Products > Disease Areas > Renal Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Farnesyl Transferase | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-172423
• CAS No.: 3065226-39-0
• Molecular Formula: C29H20N6O
• Molecular Weight: 468.51
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source